Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ANIK | DEFA14A | neutral | 3/10 | Anika Therapeutics filed a supplement to its proxy statement correcting the disclosure of stock options outstanding unde | Jun 1, 2026 |
| GLAXF | 6-K | neutral | 1/10 | GSK filed a routine 6-K on June 1, 2026, disclosing its total voting rights as of May 31, 2026. The company reported 4,3 | Jun 1, 2026 |
| AZN | 6-K | neutral | 2/10 | AstraZeneca filed a 6-K reporting the admission of 14,120 ordinary shares to trading on the London Stock Exchange, issue | Jun 1, 2026 |
| AZN | 6-K | neutral | 1/10 | AstraZeneca filed a routine 6-K disclosing its total voting rights as of 31 May 2026. The company reported 1,551,009,750 | Jun 1, 2026 |
| LEGN | PRESS-RELEASE | bullish | 6/10 | Legend Biotech presented early clinical data for LB2102 (DLL3 CAR-T) in SCLC/LCNEC at ASCO, showing manageable safety an | Jun 1, 2026 |
| VALN | 6-K | neutral | 2/10 | Valneva announced participation in investor conferences (Jefferies, Oddo BHF, BNP Paribas) and a travel medicine confere | Jun 1, 2026 |
| GLAXF | 6-K | neutral | 2/10 | GSK plc disclosed routine open-market share repurchases totaling 1,248,271 ordinary shares between May 26-29, 2026, as p | Jun 1, 2026 |
| LEGN | 6-K | bullish | 6/10 | Legend Biotech presented first-in-human Phase 1 data for LB2102 (DLL3-targeted CAR-T) in solid tumors at ASCO 2026, show | Jun 1, 2026 |
| RVRC | 8-K | neutral | 2/10 | Revium Rx. announced the resignation of CFO Arie Gordashnikov effective May 27, 2026, with no reported disagreement. The | Jun 1, 2026 |
| ONCY | 8-K | neutral | 3/10 | Oncologics Biotech announced initial preclinical data showing pelareorep combined with RAS inhibitors demonstrates great | Jun 1, 2026 |
| SILO | 8-K | neutral | 2/10 | Silo Pharma announced a 1-for-15 reverse stock split effective June 2, 2026, reducing shares outstanding from ~16.27M to | Jun 1, 2026 |
| IFF | 8-K | bullish | 7/10 | IFF entered into a definitive agreement to sell its Food Ingredients business to CVC Capital Partners for approximately | Jun 1, 2026 |
| DARE | DEFA14A | neutral | 2/10 | Dare Bioscience filed a DEFA14A on June 1, 2026, containing social media posts urging shareholders to vote ahead of the | Jun 1, 2026 |
| AIM | PRESS-RELEASE | neutral | 4/10 | AIM ImmunoTech announced ahead-of-schedule enrollment completion for its Phase 2 DURIPANC trial (Ampligen + Imfinzi in m | Jun 1, 2026 |
| LIXT | 8-K | bullish | 6/10 | LIXTE Biotechnology announced a strategic transformation into an AI energy infrastructure equipment & services platform, | Jun 1, 2026 |
| EWTX | 8-K | bullish | 8/10 | Edgewise Therapeutics announced an asset purchase agreement to sell its neuromuscular program, including the sevasemten | Jun 1, 2026 |
| TTRX | 8-K | bullish | 6/10 | Turn Therapeutics reported positive interim Phase 2 data for GX-03 in moderate-to-severe atopic dermatitis, showing rapi | Jun 1, 2026 |
| VXRT | DEFA14A | neutral | 5/10 | Vaxart filed definitive additional proxy materials urging shareholders to vote FOR its six director nominees at the July | Jun 1, 2026 |
| BAK | 6-K | neutral | 6/10 | Braskem filed a 6-K containing a management proposal for an Extraordinary General Meeting (EGM) on June 8, 2026, to refo | Jun 1, 2026 |
| ADTX | 8-K | neutral | 4/10 | Aditxt's co-founder and CEO Amro Albanna resigned, along with director Shahrokh Shhabang and COO Rowena Albanna. The boa | Jun 1, 2026 |
| FATE | PRESS-RELEASE | bullish | 6/10 | Fate Therapeutics presented early Phase 1 data for FT836, an off-the-shelf CAR T-cell therapy targeting MICA/B in solid | Jun 1, 2026 |
| IRON | PRESS-RELEASE | neutral | 4/10 | Disc Medicine launched an expanded access program (EAP) for bitopertin in erythropoietic protoporphyria (EPP)/X-linked p | Jun 1, 2026 |
| NCNA | 6-K | neutral | 3/10 | NuCana plc announced the appointment of Ian Webster as permanent Chief Financial Officer, effective June 1, 2026. Webste | Jun 1, 2026 |
| NXTC | 8-K | bullish | 6/10 | NextCure presented Phase 1 dose escalation data for its CDH6-targeting ADC, SIM0505, at ASCO 2026, showing a 55% ORR in | Jun 1, 2026 |
| RLYB | 425 | bullish | 7/10 | Rallybio Corp (RLYB) filed this 425 communication to confirm the definitive merger agreement entered into on May 31, 202 | Jun 1, 2026 |
| RLYB | 8-K | bullish | 7/10 | Rallybio Corp (RLYB) entered into a definitive merger agreement to be acquired by Avenzo Therapeutics in a reverse-merge | Jun 1, 2026 |
| CLRB | PRESS-RELEASE | bullish | 7/10 | Cellectar Biosciences announced positive Phase 2 CLOVER WaM data at ASCO for iopofosine I 131 in post-BTKi Waldenström m | Jun 1, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's filed a routine 6-K furnishing a notice of upcoming investor meetings with Bank of America on June 5, 2026. | Jun 1, 2026 |
| IMTX | 6-K | bullish | 7/10 | Immatics N.V. filed a 6-K on June 1, 2026, reporting updated Phase 1 clinical data for three pipeline candidates present | Jun 1, 2026 |
| JSPRW | 8-K | bearish | 6/10 | Jasper Therapeutics announced its Board has initiated a comprehensive review of strategic alternatives to maximize share | Jun 1, 2026 |